Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.4%

2 terminated/withdrawn out of 13 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

15%

2 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

4 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

6(46.2%)

Phase 2

4(30.8%)

Phase 3

2(15.4%)

Early Phase 1

1(7.7%)

13Total

Phase 1(6)

Phase 2(4)

Phase 3(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials

NCT06056830Phase 3Recruiting

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Role: lead

NCT04868604Phase 1Recruiting

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Role: lead

NCT06970847Phase 3Recruiting

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Role: lead

NCT05407311Phase 2Completed

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

Role: lead

NCT04023331Phase 1Terminated

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Role: lead

NCT05633160Phase 1Terminated

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

Role: lead

NCT06907641Phase 2Recruiting

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

Role: collaborator

NCT04438304Phase 2Completed

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Role: lead

NCT05249127Phase 1Completed

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Role: lead

NCT05613842Phase 2Completed

Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)

Role: collaborator

NCT04839367Phase 1Completed

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

Role: lead

NCT04440956Early Phase 1Completed

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

Role: lead

NCT03936426Phase 1Completed

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Role: lead

All 13 trials loaded